BOOK NOW

Proventa International's 11th Annual

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2024

Wednesday, 15th May 2024 | **Hyatt Regency Princeton**

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Featuring Industry Leaders and Decision Makers:

Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

Yushma Bhurruth-Alcor
Executive Director Of Chemistry
Remedy Plan Therapeutics

Andrew Zhang
Director, Head of Chemical Biology
AstraZeneca

Eileen Carry
Chief Scientific Officer
Zena Therapeutics Inc.

Gunaretnam Rajagopal
Venture Partner
Samsara Biocapital

Huijun Wang
Head of Computational Drug Design
Deerfield Management

Tanweer Khan
Director, Discovery Chemistry
aTai Life Sciences

20 ROUNDTABLE DISCUSSIONS

5 TRACKS

2 KEYNOTE PRESENTATIONS

1 PANEL DISCUSSION

1 LOCATION

What Makes Our Strategy Meetings So Unique?

Proud to Partners with:

curia | eMolecules | PELAGO BIOSCIENCE | IKTOS Artificial Intelligence for new drug design | NovAliX

Scan to Register

PROVENTA INTERNATIONAL
proventainternational.com
UK: +44 (0)208 124 6417
US: +1 (617) 340 2564
info@proventainternational.com
Proventa International
@proventaintl
@proventainternational

Proventa International's Strategy Meetings are a completely unique experience.

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2024

Wednesday 15th May 2024 | Hyatt Regency Princeton

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Medicinal Chemistry

- Medicinal Chemistry
- R&D
- Drug Discovery
- Computational Chemistry
- Cheminformatics
- CMC
- External Innovation
- Pre-Clinical
- Artificial Intelligence

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/
- Sovereign Wealth Fund
- Angel

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational

PROVENTA INTERNATIONAL

Facilitator Faculty

Jim LaRocque
Senior Research Scientist III, Assay Development & Screening
Curia

Mark Wolf
Director, Medicinal Chemistry
Curia

Matthew Surman
Associate Director, Medicinal Chemistry
Curia

Helena Almqvist
Project Advisor, Business Development
Pelago Bioscience

Rick Ewing
VP, Head of Chemistry
Rapafusyn Pharmaceuticals

Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

Andrew Zhang
Director, Head of Chemical Biology
AstraZeneca

David James
Senior VP Business Development
eMolecules

Ernane Souza, PhD, RPh
Assistant Director, Translational PKPD and DMPK
Supernus Pharmaceuticals Inc

Eileen Carry
Chief Scientific Officer
Zena Therapeutics Inc

Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC

Gunaretnam Rajagopal
Venture Partner,
Samsara Biocapital

Huijun Wang
Head of Computational Drug Design
Deerfield Management

ML Ujwal
Associate Director, Data Science
Janssen

Tanweer Khan
Director, Discovery Chemistry
aTai Life Sciences

Dongming Shen
Vice President Chemistry
Viva Star Biosciences

Yushma Bhurruth-Alcor
Executive Director Of Chemistry
Remedy Plan Therapeutics

2024 Sponsors

LEAD SPONSOR

Curia is a Contract Research, Development and Manufacturing Organization with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state of the art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com

CO-HOST SPONSOR

eMolecules is driven to remove the fear, hurt and heartbreak of health problems worldwide, by enabling scientists to accelerate their research to find the cures. To achieve this eMolecules provides business intelligence data and integrated ecommerce software for screening compound, chemical building blocks and primary antibody supply chains. These tools combined with their acquisition, aggregation and analytical services greatly empower drug discovery researchers working in the pharmaceutical, biotechnology, academia, CRO and agrochemical industries. A privately owned company, eMolecules was founded in 2005 at its San Diego headquarters and has offices in Boston and London employing over 40 people across the three sites.

PARTNERING SPONSORS

PELAGO BIOSCIENCE

IKTOS Artificial Intelligence for new drug design

KEY OPINION LEADER

NovAliX

Agenda at a Glance

MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024
Wednesday 15th May 2024 | Hyatt Regency Princeton

TIME EST	TRACK 1 AI/ML AND DESIGN & SYNTHESIS	TRACK 2 INNOVATIVE AND EMERGING MODALITIES	TRACK 3 CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION AND UNDRUGGABLES	TRACK 4 HIT IDENTIFICATION / LEAD OPTIMIZATION	TRACK 5 INTEGRATED DRUG DISCOVERY
08:00 - 08:30	BREAKFAST & REGISTRATION				
08:30 - 09:00	OPENING KEYNOTE PRESENTATION: Non-Degrading molecular Glues for Discovering Inhibitors for Hard to Drug Targets PRESENTER: Rick Ewing, *VP, Head of Chemistry*, Rapafusyn Pharmaceuticals				
09:00 - 10:00 PHARMA/ BIOTECH	**Advancing the Frontier: Harnessing Deep Learning and Generative AI for Molecule Design and Optimization in Chemistry** Abhijat Vatsyayan, *Head of Artificial Intelligence*, Taiho Oncology	**Examining the Mechanism and Effects of Induced Proximity Modalities**	**Pioneering Chemical and Proteomics Approaches: Unraveling Efficacy and Safety in Small Molecule and Protein Degradation Across Multiple Therapeutic Frontiers** Andrew Zhang, *Director, Head of Chemical Biology*, AstraZeneca	**Using Computational Methods to Improve Precision and Efficiency in Lead Optimization and Hit Identification** Huijun Wang, *Head of Computational Drug Design*, Deerfield Management	**Integrated Drug Discovery for Maximal Real-World Clinical Impact** Eileen Carry, *Founder & CEO*, Zena Therapeutics Inc
10:00 - 10:05	REFRESHMENT BREAK				
10:05 - 10:25	NETWORKING / 1-1 MEETINGS				
10:25 - 10:45	NETWORKING / 1-1 MEETINGS				
10:45 - 11:05	NETWORKING / 1-1 MEETINGS				
11:10 - 12:10 SOLUTION	**The Utility of Ultra-Large Virtual Chemical Spaces: Opportunities, Challenges and What's Next?** David James, *Senior VP Business Development*, eMolecules EMOLECULES	**Investigating the Application of DELs for the Discovery of Other Modalities** SPONSOR	**Overcoming Drug Resistance and Undruggable Targets with Chemical Biology and Targeted Protein Degradation** Mark Wolf, *Director, Medicinal Chemistry*, Curia CURIA	**Understanding The Future Of High Throughput Screening And How We Might Be Able To Reach Undruggable Targets** Jim LaRocque, *Senior Research Scientist III, Assay Development & Screening*, Curia CURIA	**The Future Of Computer-Aided Drug Design (CADD) In Various Stages Of The Drug Development Pipelines, As Well As Pharma-Technological Advances** Matthew Surman, *Associate Director, Medicinal Chemistry*, Curia CURIA
12:15 - 13:15 PHARMA/ BIOTECH	**Disruptive techs: Blockchain** Frank Leu, *Founder & Managing Member/ Managing Member*, BioPharMatrix LLC/ Novapeutics LLC	**Unveiling the Next Wave of Drug Discovery: Discovering Cutting-Edge Technologies and Approaches** Tanweer Khan, *Director, Discovery Chemistry*, aTai Life Sciences	**Identifying "Difficult-to-Drug" Targets with Chemical Biology Approaches** Andrew Zhang, *Director, Head of Chemical Biology*, AstraZeneca	**Efforts for "Failing Fast and Failing Early." i.e., What to Do Early in Lead Generation and Lead Optimization** Dongming Shen, *Vice President Chemistry*, Viva Star Biosciences	**Breaking Boundaries in Drug Discovery: High-Throughput Phenotypic Screening for Identifying Transformative Molecules and Novel Mechanisms for Clinical Translation** Yushma Bhurruth-Alcor, *Executive Director Of Chemistry*, Remedy Plan Therapeutics
13:15 - 14:00	NETWORKING LUNCH				
14:00 - 14:20	NETWORKING / 1-1 MEETINGS				
14:20 - 14:40	NETWORKING / 1-1 MEETINGS				
14:40 - 15:10	AFTERNOON KEYNOTE PRESENTATION				
15:10 - 16:10 PHARMA/ BIOTECH	**Exploiting the Selectivity and Efficiency of Enzymes in Complex Molecule Synthesis (Topic TBC)** ML Ujwal, *Associate Director, Data Science*, Janssen	**Innovating the Future of Healthcare: Integrating AI, Data Science, Genetics, and Genomics into Biotech & Pharma R&D Strategies** Gunaretnam Rajagopal, *Venture Partner*, SamSara Biocapital	**Methods of Computation and Cheminformatics for Chemical Synthesis and Hit Finding for Tough Targets and New Therapeutic Approaches**	**From design to clinical candidate - efficient strategies for lead optimization** Yushma Bhurruth-Alcor, *Executive Director Of Chemistry*, Remedy Plan Therapeutics	**Exploring Translational Challenges and Triumphs in Integrated Drug Discovery for Real-World Clinical Impact (Topic TBC)** Ernane Souza, PhD, RPh, *Assistant Director, Translational PKPD and DMPK*, Supernus Pharmaceuticals Inc
16:10 - 16:15	AFTERNOON REFRESHMENT BREAK				
16:15 - 16:45	KEYNOTE PRESENTATION: Drug Discovery at the melting point: CETSA® PRESENTER: Helena Almqvist, *Project Advisor, Business Development*, Pelago Bioscience				
16:45 - 17:15	PANEL DISCUSSION: Bridging Science and Investment: A Dialogue on Drug Discovery, Venture Strategies, Biotech Progress, and the Revolutionary Landscape of Pharmaceuticals PRESENTER: Gunaretnam Rajagopal, *Venture Partner*, Samsara Biocapital				
17:15 - 18:30	DRINKS & CANAPES RECEPTION				

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/ pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

08:30 - 09:00 ET **OPENING KEYNOTE PRESENTATION**

Non-Degrading molecular Glues for Discovering Inhibitors for Hard to Drug Targets

Rick Ewing
VP, Head of Chemistry
Rapafusyn Pharmaceuticals

ABOUT THE SPEAKER

Rick Ewing is VP, Head of Chemistry at Rapafusyn, a platform company focused on Type I molecular glues. Previous to Rapafusyn, Rick held the position of VP, Head of Drug Discovery at the Barer Institute. Prior to Barer, Rick was a senior director in Discovery Chemistry at Bristol Myers Squibb where he led medicinal chemistry teams to deliver 15 development candidates in the therapeutic areas of cardiovascular, diabetes, obesity, and heart failure. Among the development candidates is Milvexian, a first in class Factor XIa inhibitor currently in PIII development. Rick is coinventor on 79 patents, and co-author on 77 publications. In 2023, Rick was awarded the ACS Philadelphia Section Award for distinguished achievement in medicinal chemistry. In 2023, Rick also received the Edison Patent Award in Biotechnology Innovation with colleagues from BMS and Scripps Research. In 2021, he was awarded the ACS Fellow by the American Chemical Society and in 2018 received the Ondetti-Cushman award for leadership of the FXIa drug discovery team. Prior to Bristol Myers Squibb, Rick spent 12 years at RPR (now Sanofi). Rick received his Ph.D. in Organic Chemistry from U. Penn.

14:40 - 15:10 ET **AFTERNOON KEYNOTE PRESENTATION**

Topic TBC

Speaker TBC

curia

ABOUT THE SPEAKER

Speaker TBC

16:15 - 16:45 ET **KEYNOTE PRESENTATION**

Drug Discovery at the melting point: CETSA®

Helena Almqvist
Project Advisor, Business Development
Pelago Bioscience

PELAGO BIOSCIENCE

ABOUT THE SPEAKER

Helena Almqvist is a Project Advisor at Pelago Bioscience, where she acts as a scientific liaison for key accounts and develops customized projects. With more than 15 years of experience in pre-clinical drug discovery, she joined the company in 2018 to accelerate the CETSA® HT screening platform and lead CETSA projects tailored to clients. Helena is an expert in assay development and screening, having worked in small and large pharma settings as well as a project manager at a national infrastructure. She played a crucial role in adapting the CETSA method for screening and executing the first primary screening campaign using CETSA.

16:45 - 17:15 ET **PANEL DISCUSSION**

Bridging Science and Investment: A Dialogue on Drug Discovery, Venture Strategies, Biotech Progress, and the Revolutionary Landscape of Pharmaceuticals

Gunaretnam Rajagopal
Venture Partner
Samsara BioCapital

ABOUT THE SPE AKER

Guna's expertise encompasses the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He has led global initiatives focused on advancing cross-disciplinary basic research, translational & clinical programs in collaboration with academia and national/international pre-competitive consortiums. Guna's academic career spans undergraduate degree from the University of Malaya (1986), PhD in Computational & Theoretical Physics from Georgia Tech (1987-1991), post-doctoral training at the Cavendish Laboratory, University of Cambridge, rising to Assistant Director of Research and elected a Fellow of Jesus College Cambridge (1991-2000). He was the founding Executive Director of the Bioinformatics Institute at the BIOPOLIS, Singapore (2000-2007), led the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of Advanced Studies in Princeton (2007-2012). He joined Janssen R&D to lead efforts to develop and deploy Computational Analytics, Informatics and Data Science capabilities to support global discovery, translational, development and clinical programs (2012-2022). He retired as Scientific Fellow and Global Head of Computational Sciences and joined Samsara Biocapital as a Venture Partner.

Event Day

TRACK 1

AI/ML and Design & Synthesis

Large quantities of biological and medical data brought by increased digitalization in the industry go hand in hand with next-level machine cognition to aid efforts involving drug discovery & development, synthesis, drug repurposing, modeling & simulation, predicting protein attachment, computer-Aided drug design (CADD), and beyond. This track explores the verifiable use of advanced technologies to analyze data, predict structure and activity, aid in hit finding and more.

MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024
15th May 2024, Wednesday | Hyatt Regency Princeton

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Advancing the Frontier: Harnessing Deep Learning and Generative AI for Molecule Design and Optimization in Chemistry

- Innovative Approaches to Molecule Design
- Deep Learning for Property Prediction
- Optimization Strategies for Lead Development
- Case Studies and Real-world Applications
- Ethical Considerations and Future Directions

Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

ABOUT THE SPEAKER
Trained as an aerospace engineer, Abhijat has had a career spanning over 23 years most of it dedicated to helping to bring life-extending medicines to patients through the use of technology. In this 20+ years working at pharmaceutical companies, he collaborates with individuals from diverse backgrounds, applying analytical, design, and creative problem-solving skills to the complex challenge of drug development. Abhijat also has a foundational understanding of artificial intelligence, including machine learning, and has built simplified deep-learning frameworks to educate and present machine-learning concepts. Finally, he is also a proud co-founder of multiple failed startups.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

The Utility of Ultra-Large Virtual Chemical Spaces: Opportunities, Challenges and What's Next?

- How are ultra-large spaces being used to speed up and improve virtual screening programs?
- What are the most useful emerging technologies that facilitate the navigation of ultra-large spaces?
- What makes some of the more recently developed ultra-large spaces different compared to previous libraries?
- How do we more effectively bridge the gap between virtual compounds and synthesis into real molecules?

David James
Senior VP Business Development
eMolecules

ABOUT THE SPEAKER
David is responsible for scientific business development working closely with new and existing Chemistry departments to design efficient chemistry operations solutions using eMolecules platforms and capabilities. David has been with eMolecules for over 10 years in a variety of roles, including Corporate Development, Product Development and Sales resulting in high growth for the company. Before joining eMolecules, David was a medicinal chemist with Synta Pharmaceuticals and was a member of research teams that produced three successful IND submissions. David has a Ph.D. in organic chemistry from Queensland University of Technology in Brisbane, Australia.

12:15 - 13:15 ET ROUNDTABLE 3

Disruptive techs: Blockchain

- Innovative Solutions: Exploring the Impact of disruptive techs on Pharmaceutical R&D
- Navigating the Frontier: The Role of disruptive techs in Expediting Drug Development Processes
- The influence of disruptive techs on Bioinformatics in Modern Drug Development

Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC

ABOUT THE SPEAKER
Speaker TBC

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

Exploiting the Selectivity and Efficiency of Enzymes in Complex Molecule Synthesis (Topic TBC)

ML Ujwal
Associate Director, Data Science
Janssen

ABOUT THE SPEAKER
Speaker TBC

16:10 - 16:15 ET AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 ET KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 ET PANEL DISCUSSION
See Page 6

17:15 - 18:30 ET DRINKS & CANAPES RECEPTION

Event Day

Innovative and Emerging Modalities

TRACK 2

Despite the reinvigorated R&D engine and reinstated productivity, challenges and opportunities remain unanswered such as optimized druggability, pharmacokinetics and safety, enhanced bioavailability, DNA-Encoded Library, Small and Large Molecules Enhancement, Covalent Fragment Libraries, and more. This track aims to tackle these current barriers, formulate an outlook

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Examining the Mechanism and Effects of Induced Proximity Modalities

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Investigating the Application of DELs for the Discovery of Other Modalities

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Unveiling the Next Wave of Drug Discovery: Discovering Cutting-Edge Technologies and Approaches

Tanweer Khan
Director, Discovery Chemistry
aTai Life Sciences

ABOUT THE SPEAKER
Dr. Tanweer Khan, Ph.D., is the Director of Discovery Chemistry at Atai Life Sciences since 2021. As the Head of Discovery Chemistry at Early Development, he provides senior leadership for various R&D organizations across multiple therapeutic areas. Dr. Khan coordinates research direction and oversees a diverse portfolio of psychedelic inspired/GPCR drug discovery programs with a focus on mental health, neuropsychiatric disorders, and neurodegenerative diseases. He excels in building high-performance internal and external CRO teams through effective communication, cross-functional collaboration, and fostering team creativity to drive synergy.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

Innovating the Future of Healthcare: Integrating AI, Data Science, Genetics, and Genomics into Biotech & Pharma R&D Strategies

Gunaretnam Rajagopal
Venture Partner
Samsara BioCapital

ABOUT THE SPEAKER
See Page 6

16:10 - 16:15 ET AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 ET KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 ET PANEL DISCUSSION
See Page 6

17:15 - 18:30 ET DRINKS & CANAPES RECEPTION

Event Day

Chemical Biology, Targeted Protein Degradation and Undruggables

TRACK 3

This track tackles pressing topics that interrogate and discern biological function by exploring small and large molecule modulation, undruggable targets, Target Protein Degradation, Deep Learning, And Molecular Simulations, and more, to understand probe development better and uncover novel and therapeutically relevant targets.

MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024
15th May 2024, Wednesday | Hyatt Regency Princeton

08:00 - 08:30 ET ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Pioneering Chemical and Proteomics Approaches: Unraveling Efficacy and Safety in Small Molecule and Protein Degradation Across Multiple Therapeutic Frontiers

- Introductions of participants and topics – how do you use mass spectrometry-based proteomics in your R&D organization?
- MS-based proteomics, including discovery proteomics, can be run at a higher throughput now than before (e.g. 100 samples per day), albeit with a penalty on coverage. How can we best use higher throughput proteomics to inform our compound prioritization and SAR generation?
- What is the best way to incorporate proteomics datasets into safety prediction models? What proteomics data will be needed? How much data is "enough"?

Andrew Zhang
Director, Head of Chemical Biology
AstraZeneca

ABOUT THE SPEAKER
Andrew Zhang is the Director and Head of Chemical Biology at AstraZeneca. He joined AstraZeneca in 2013 and his team's remit is using chemical probes and mass spectrometry-based discovery proteomics for deconvoluting the mechanism of drug target engagement towards identifying drivers of efficacy and adverse safety events. Andrew's scientific career started at the University of California, Berkeley, where he obtained a B.S. in Chemistry and a B.A. in Molecular and Cell Biology, and he received his Ph.D. with Professor David Spiegel at Yale working on small molecule immunomodulators. Andrew trained as a postdoctoral fellow at the Ontario Institute for Cancer Research (Toronto, Canada) with Dr. Rima Al-awar.

10:00 - 11:10 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Overcoming Drug Resistance and Undruggable Targets with Chemical Biology and Targeted Protein Degradation

- How are advancements in chemical biology reshaping our approach to combat drug resistance, particularly in the context of diseases like cancer and bacterial infections?
- Proteolysis targeting chimeras (PROTACs) are a powerful tool for targeted protein degradation. What advantages do they offer over traditional small molecule inhibitors in regards to drug resistance and undruggable targets?
- What challenges do protein degraders face in discovery and development, and how are these challenges being addressed?
- How can computational techniques, modeling, help in the design and optimization of compounds for targeting undruggable proteins or overcoming resistance mechanisms?

Mark Wolf
Director, Medicinal Chemistry
Curia

ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Identifying "Difficult-to-Drug" Targets with Chemical Biology Approaches

- What are the characteristics of these "difficult" targets that make them so difficult to drug?
- What approaches can we take to uncover the key mechanisms of these targets in order to influence Hit ID and LG campaigns?
- How do we validate new targets and mechanisms? Is the traditional target knockdown enough, or what else should we include in the validation package?

Andrew Zhang
Director, Head of Chemical Biology
AstraZeneca

ABOUT THE SPEAKER
See Previous RT1

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 EST ROUNDTABLE 4

Methods of Computation and Cheminformatics for Chemical Synthesis and Hit Finding for Tough Targets and New Therapeutic Approaches

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

16:10 - 16:15 ET AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 ET KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 ET PANEL DISCUSSION
See Page 6

17:15 - 18:30 ET DRINKS & CANAPES RECEPTION

Event Day

Hit Identification / Lead Optimization

TRACK 4

The process of discerning the properties associated with each hit compound is multi-dimensional and impossibly challenging giving rise to the process of eliminating weekly active compounds - Hit to Lead. This track will investigate the steps between target validation to lead optimization, Structure-Based Drug Design Lead, High Throughput Screening, Accelerating Hit-To-Lead Optimization and Progress of Compounds for Lead Optimization, and more.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Using Computational Methods to Improve Precision and Efficiency in Lead Optimization and Hit Identification

Huijun Wang
Head of Computational Drug Design
Deerfield Management

ABOUT THE SPEAKER

Huijun Wang, Ph.D., is the Head of Computational Drug Design, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Wang was most recently Director, Computational Drug Design at Agios Pharmaceuticals. Before Agios, she was an Associate Principal Scientist, Modeling and Informatics at Merck and a Senior Scientist at Pfizer. Dr. Wang is an expertise in computational drug design including chemical biology, virtual screening, AI/ML, structure/ligand-based design, ADMET prediction, etc. Dr. Wang has over 18 years experiences in AI/ML, NLP, FAIR data management, cheminformatics, bioinformatics, and their applications in drug discovery.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Understanding The Future Of High Throughput Screening And How We Might Be Able To Reach Undruggable Targets.

- Engineered cellular reporter assays vs Imunoflorecence HCS to address challenging targets?
- Cellular HTS with biophysical hit validation vs Biochemical HTS with cellular hit validation?
- How can label free HTS enable the identification of hits for unexplored targets ?
- What innovative screening approaches or assays are emerging to access unexplored target space and accelerate hit identification?
- What role does computational modeling and virtual screening play in identifying focused libraries for efficient hit identification?
- How can we utilize HTS technologies to broaden lead optimization selectivity profiling to drive lead design?

Jim LaRocque
Senior Research Scientist III,
Assay Development & Screening
Curia

ABOUT THE SPEAKER

Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Efforts for "Failing Fast and Failing Early." i.e., What to Do Early in Lead Generation and Lead Optimization

Dongming Shen
Vice President Chemistry
Viva Star Biosciences

ABOUT THE SPEAKER

I started my industrial career at Mobil Oil's Central Research Laboratory in Princeton, NJ. After five years at Mobil, I moved to Merck at Rahway where I worked on and led various medicinal chemistry projects over the next 21 years. After Merck, I moved to IFM therapeutics, where I discovered a NLRP3 antagonist which was moved into PhI trial after about 2 years at the company and it was sold to Novartis. After a brief stint at Odyssey Therapeutics, I am currently head of Global Chemistry at Viva Star Biosciences, a China based small molecule focused biotechnology company.

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

From design to clinical candidate - efficient strategies for lead optimization

Yushma Bhurruth-Alcor
Executive Director Of Chemistry
Remedy Plan Therapeutics

ABOUT THE SPEAKER

Yushma Bhurruth-Alcor joined Remedy Plan Therapeutics in 2018, where she is Executive Director, Chemistry. She brings extensive pharmaceutical drug discovery experience to the team, having worked in the pharmaceutical industry for companies such as GlaxoSmithKline, Galderma, and Johnson & Johnson, where she successfully developed novel clinical drug candidates. After graduating from the ESPCI in Paris, Yushma obtained her Ph.D. in Chemistry from Imperial College London. She has 15 years of experience in drug discovery and development, with extensive experience spanning a wide range of target classes (enzymes, ion channels, GPCRs, PPIs) across several therapeutic areas (oncology, dermatology, metabolic and respiratory diseases)

16:10 - 16:15 ET AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 ET KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 ET PANEL DISCUSSION
See Page 6

17:15 - 18:30 ET DRINKS & CANAPES RECEPTION

Event Day

TRACK 5

Integrated Drug Discovery

Overcoming the high attrition rates of the development process, particularly in drug discovery and optimization remains a significant hurdle and a top priority in the pharma and biotech sector. Here we will explore effective strategies to break down discipline segmentation and foster an improved integrated approach to drug discovery.

08:00 - 08:30 ET BREAKFAST & REGISTRATION

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 ET ROUNDTABLE 1

Integrated Drug Discovery for Maximal Real-World Clinical Impact

- Learning from end-users and prescribers to identify real-world pain points.
- Resources available to help with costumer discovery and exploration of the market.
- Integrating learnings to guide direction of research and development.

Eileen Carry
Chief Scientific Officer
Zena Therapeutics

ABOUT THE SPEAKER

Eileen Carry, PhD is founder and Chief Scientific Officer of Zena Therapeutics Inc. Zena Therapeutics is a drug discovery company, spun-out of Rutgers University, designing new medications for mental health and addiction by improving safety profiles. Currently the Zena's research, funded by a phase I NIH STTR grant, focuses on acute anxiolytic compounds that do not increase the risk of overdose if taken concomitantly with other CNS depressing substances such as opioids and alcohol. Dr. Carry is determined to pave the way for improving the safety of CNS pharmaceuticals by minimizing harm caused by misuse.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

The Future Of Computer-Aided Drug Design (CADD) In Various Stages Of The Drug Development Pipelines, As Well As Pharma-Technological Advances

- Over the past 5–10 years, what have been some of the most significant advances in Computer-Aided Drug Design and how do you see these continuing to develop over the next 5–10 years?
- How have advances in protein crystallography and virtual library screening impacted the role of CADD in drug discovery?
- Over the next 5–10 years, in which stage of drug development (target identification/validation; hit discovery and lead validation; lead optimization; preclinical development; clinical development) do you see CADD making the most substantial impact?
- What do you see as the major challenges to Computer-Aided Drug Design over then next 5–10 years?

Matthew Surman
Associate Director,
Medicinal Chemistry
Curia

ABOUT THE SPEAKER

Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Breaking Boundaries in Drug Discovery: High-Throughput Phenotypic Screening for Identifying Transformative Molecules and Novel Mechanisms for Clinical Translation

Yushma Bhurruth-Alcor
Executive Director Of Chemistry
Remedy Plan Therapeutics

ABOUT THE SPEAKER

See Page 10

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 ET ROUNDTABLE 4

Exploring Translational Challenges and Triumphs in Integrated Drug Discovery for Real-World Clinical Impact (Topic TBC)

Ernane Souza, PhD, RPh
Assistant Director, Translational PKPD and DMPK
Supernus Pharmaceuticals Inc

ABOUT THE SPEAKER

Speaker TBC

16:10 - 16:15 ET AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 ET KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 ET PANEL DISCUSSION
See Page 6

17:15 - 18:30 ET DRINKS & CANAPES RECEPTION



Pharma
FEATURES

Find your new partner,
explore our digital storefronts

www.pharmafeatures.com

Contact us to discuss how we can help generate growth for your business

Dex Marco Guibelondo
Marketing Content Writer, Proventa International
Editor-in-Chief, PharmaFEATURES

dex@proventainternational.com

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2024

Wednesday 15th May 2024 | Hyatt Regency Princeton

Delegate Price *Pharma/Biotech/ Academia	**$699**
Vendor/ Service Provider	**$2999**

Hotel & Venue

HYATT REGENCY®

Hyatt Regency Princeton

Hyatt Regency Princeton offers a convenient location close to Route 1 and the Princeton Junction Train Station, making it the perfect location to explore the area. Business travelers will enjoy thoughtful amenities, such as large work desks with enhanced lighting and free Wi-Fi.

BOOK NOW!
We only have limited rooms available!

Hotel Details > | Map & Directions >






OUR FACE TO FACE MEETING IN MAY 2024

STRATEGY MEETING EAST COAST USA
Hyatt Regency Princeton

- MAY 14 — DRUG DISCOVERY BIOLOGY & BIOINFORMATICS — STRATEGY MEETING EAST COAST USA 2024
- MAY 15 — MEDICINAL CHEMISTRY — STRATEGY MEETING EAST COAST USA 2024
- MAY 16 — CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN — STRATEGY MEETING EAST COAST USA 2024

STRATEGY MEETING WEST COAST USA
Hard Rock Hotel San Diego

- MAY 21 — DRUG DISCOVERY BIOLOGY & BIOINFORMATICS — STRATEGY MEETING WEST COAST USA 2024
- MAY 22 — MEDICINAL CHEMISTRY — STRATEGY MEETING WEST COAST USA 2024
- MAY 23 — CLINICAL OPERATIONS & CLINICAL TRIAL SUPPLY CHAIN — STRATEGY MEETING WEST COAST USA 2024

Visit us on our website to know more about our meetings

www.proventainternational.com